These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis. Chu Miow Lin D; Mulleman D; Azzopardi N; Griffoul-Espitalier I; Valat JP; Paintaud G; Goupille P Scand J Rheumatol; 2010; 39(1):97-8. PubMed ID: 20132079 [No Abstract] [Full Text] [Related]
3. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Haibel H; Brandt HC; Song IH; Brandt A; Listing J; Rudwaleit M; Sieper J Ann Rheum Dis; 2007 Mar; 66(3):419-21. PubMed ID: 16901959 [TBL] [Abstract][Full Text] [Related]
4. Exacerbation of infliximab-induced palmoplantar psoriasis under ustekinumab therapy in a patient with ankylosing spondylitis. Safa G; Martin A; Darrieux L J Clin Rheumatol; 2011 Oct; 17(7):385-6. PubMed ID: 21946468 [No Abstract] [Full Text] [Related]
5. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. Gonzalez-Lopez L; Garcia-Gonzalez A; Vazquez-Del-Mercado M; Muñoz-Valle JF; Gamez-Nava JI J Rheumatol; 2004 Aug; 31(8):1568-74. PubMed ID: 15290737 [TBL] [Abstract][Full Text] [Related]
6. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. Cantini F; Niccoli L; Benucci M; Chindamo D; Nannini C; Olivieri I; Padula A; Salvarani C Arthritis Rheum; 2006 Oct; 55(5):812-6. PubMed ID: 17013842 [No Abstract] [Full Text] [Related]
7. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. van der Heijde D; Da Silva JC; Dougados M; Geher P; van der Horst-Bruinsma I; Juanola X; Olivieri I; Raeman F; Settas L; Sieper J; Szechinski J; Walker D; Boussuge MP; Wajdula JS; Paolozzi L; Fatenejad S; Ann Rheum Dis; 2006 Dec; 65(12):1572-7. PubMed ID: 16968715 [TBL] [Abstract][Full Text] [Related]
8. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Davis JC; van der Heijde DM; Braun J; Dougados M; Cush J; Clegg D; Inman RD; Kivitz A; Zhou L; Solinger A; Tsuji W Ann Rheum Dis; 2005 Nov; 64(11):1557-62. PubMed ID: 15843448 [TBL] [Abstract][Full Text] [Related]
9. Clinimetric evaluation of the bath ankylosing spondylitis metrology index in a controlled trial of pamidronate therapy. Jauregui E; Conner-Spady B; Russell AS; Maksymowych WP J Rheumatol; 2004 Dec; 31(12):2422-8. PubMed ID: 15570645 [TBL] [Abstract][Full Text] [Related]
10. Dramatic response after an intravenous loading dose of azathioprine in one case of severe and refractory ankylosing spondylitis. Durez P; Horsmans Y Rheumatology (Oxford); 2000 Feb; 39(2):182-4. PubMed ID: 10725069 [TBL] [Abstract][Full Text] [Related]
11. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Marzo-Ortega H; McGonagle D; Jarrett S; Haugeberg G; Hensor E; O'connor P; Tan AL; Conaghan PG; Greenstein A; Emery P Ann Rheum Dis; 2005 Nov; 64(11):1568-75. PubMed ID: 15829577 [TBL] [Abstract][Full Text] [Related]
12. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Braun J; McHugh N; Singh A; Wajdula JS; Sato R Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658 [TBL] [Abstract][Full Text] [Related]
13. Methotrexate in the treatment of ankylosing spondylitis. Sampaio-Barros PD; Costallat LT; Bertolo MB; Neto JF; Samara AM Scand J Rheumatol; 2000; 29(3):160-2. PubMed ID: 10898067 [TBL] [Abstract][Full Text] [Related]
14. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. Davis JC; Van der Heijde DM; Dougados M; Braun J; Cush JJ; Clegg DO; Inman RD; de Vries T; Tsuji WH J Rheumatol; 2005 Sep; 32(9):1751-4. PubMed ID: 16142873 [TBL] [Abstract][Full Text] [Related]
15. [Methotrexate: advantages of subcutaneous administration]. Krüger K Z Rheumatol; 2008 Jul; 67(4):332-3. PubMed ID: 18443809 [No Abstract] [Full Text] [Related]
16. Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Li EK; Griffith JF; Lee VW; Wang YX; Li TK; Lee KK; Tam LS Rheumatology (Oxford); 2008 Sep; 47(9):1358-63. PubMed ID: 18573802 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study. Heinonen AV; Aaltonen KJ; Joensuu JT; Lähteenmäki JP; Pertovaara MI; Romu MK; Hirvonen HE; Similä AK; Blom ML; Nordström DC J Rheumatol; 2015 Dec; 42(12):2339-46. PubMed ID: 26472421 [TBL] [Abstract][Full Text] [Related]
18. Do low-dose anti-TNF regimens have a role in patients with ankylosing spondylitis? Yates M; Keat A; Gaffney K Rheumatology (Oxford); 2016 May; 55(5):769-72. PubMed ID: 26660639 [No Abstract] [Full Text] [Related]
19. Atypical methotrexate dermatitis and vasculitis in a patient with ankylosing spondylitis. Borman P; Bodur H; Güleç AT; Uçan H; Seçkin U; Mocan G Rheumatol Int; 2000; 19(5):191-3. PubMed ID: 10984137 [TBL] [Abstract][Full Text] [Related]
20. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]